Sanofi SA

SAN: XPAR (FRA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
€922.00QwyGbjqbmczs

Sanofi Earnings: Solid Results Led by Robust Dupixent Sales and Investments in the Pipeline

Sanofi reported solid first-quarter results largely in line with our expectations and we're holding firm to our fair value. We continue to view the stock as undervalued with the market not fully appreciating Sanofi’s long-term growth potential and developing pipeline that also reinforces the firm’s wide moat.

Sponsor Center